Trials / Unknown
UnknownNCT04216355
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT
The Feasibility of a Bridging Treatment With Low-dose Azacitidine (AZA) in Combination With Short Term CAG Derived Regimen Prior to Allogeneic Stem Cell Transplantation (Allo-HSCT) in Patients With Advanced Myelodysplastic Syndromes (MDS)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine | Low-dose AZA |
| DRUG | CAG Protocol | Short term CAG derived regimen |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-12-01
- Completion
- 2023-12-01
- First posted
- 2020-01-02
- Last updated
- 2020-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04216355. Inclusion in this directory is not an endorsement.